Highbridge Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Highbridge Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,048,585	Closed	-$44.1M	–	378
2025 Q4	$44.1M	Buy	+2,048,585	New	+$39.8M	1.41%	20
2019 Q1	–	Sell	-98,000	Closed	-$253K	–	362
2018 Q4	$253K	Buy	+98,000	New	+$333K	0.01%	337

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Highbridge Capital Management's AVDL Position: Q1 2026 in Review

Highbridge Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 2,048,585 shares — an estimated $44.1M sold.

Highbridge Capital Management first reported a position in AVDL in Q4 2018 and held it in 2 quarters. The position peaked at $44.1M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Highbridge Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Highbridge Capital Management sold 2,048,585 Avadel Pharmaceuticals shares in Q1 2026, an estimated $44.1M.
Highbridge Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Highbridge Capital Management's Avadel Pharmaceuticals position peaked at $44.1M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Highbridge Capital Management's 13F filing for Q1 2026, filed 15 May 2026.